SilkTech Biopharmaceuticals is Minneapolis based biotech company developing silk-based anti-inflammatory biotherapeutics. Currently, its lead drug candidate, Amlisimod (SDP-4) is in Phase 2 clinical trial for Dry Eye Disease.